To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel backs Emmaus' sickle cell therapy

FDA's Oncologic Drugs Advisory Committee voted 10-3 in favor of approval of Endari L-glutamine from Emmaus Life Sciences Inc. (Torrance, Calif.) to treat sickle cell disease

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE